Qyuns Therapeutics Co., Ltd. Class H

As of December 31, 2025, Qyuns Therapeutics Co., Ltd. Class H carries a market capitalization of 4.24B, placing it among publicly traded companies globally. Its enterprise value stands at 3.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Qyuns Therapeutics Co., Ltd. Class H's next confirmed earnings release is scheduled for March 26, 2027.

As of December 31, 2025, Qyuns Therapeutics Co., Ltd. Class H has 225.56M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Qyuns Therapeutics Co., Ltd. Class H maintains a current ratio of 2.22, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Qyuns Therapeutics Co., Ltd. Class H's stock has declined approximately 43.37% over the past 52 weeks. The 50-day moving average sits at 16.80, while the 200-day moving average is 17.67.

As of December 31, 2025, Qyuns Therapeutics Co., Ltd. Class H holds 1.16B in cash and equivalents against 645.49M in total debt, resulting in a net debt position of -427.74M. Total book value stands at 772.38M, with working capital of 682.12M providing operational flexibility.